The neuromodulator dopamine signals through the dopamine D2 receptor (D 2 R) to modulate central nervous system functions through diverse signal transduction pathways. D 2 R is a prominent target for drug treatments in disorders where dopamine function is aberrant, such as schizophrenia. D 2 R signals through distinct G-protein and β-arrestin pathways, and drugs that are functionally selective for these pathways could have improved therapeutic potential. How D 2 R signals through the two pathways is still not well defined, and efforts to elucidate these pathways have been hampered by the lack of adequate tools for assessing the contribution of each pathway independently. To address this, Evolutionary Trace was used to produce D 2 R mutants with strongly biased signal transduction for either the G-protein or β-arrestin interactions. These mutants were used to resolve the role of G proteins and β-arrestins in D 2 R signaling assays. The results show that D 2 R interactions with the two downstream effectors are dissociable and that G-protein signaling accounts for D 2 R canonical MAP kinase signaling cascade activation, whereas β-arrestin only activates elements of this cascade under certain conditions. Nevertheless, when expressed in mice in GABAergic medium spiny neurons of the striatum, the β-arrestin-biased D 2 R caused a significant potentiation of amphetamine-induced locomotion, whereas the G proteinbiased D 2 R had minimal effects. The mutant receptors generated here provide a molecular tool set that should enable a better definition of the individual roles of G-protein and β-arrestin signaling pathways in D 2 R pharmacology, neurobiology, and associated pathologies.
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dopamine | GPCR | functional selectivity | G protein | β-arrestin G protein-coupled receptors (GPCRs) are the largest receptor family and transmit the physiological effects of numerous biologically active molecules. GPCR signal transduction cascades account for diverse genomic, biochemical, cellular, and behavioral responses including cell fate determination, developmental reprogramming, olfactory, taste and light sensation, as well as complex behaviors mediated by neuromodulators (1). The diversity of responses to a particular hormone or neuromodulator is dictated not only by its cognate receptor but also by the ability of that receptor to engage distinct signaling pathways. For a number of GPCRs, their propensity to activate distinct G proteins can elicit diverse responses depending on the cellular environment (2). However, an even more subtle but intriguing mode of signaling has been attributed to the ability of a receptor to activate signaling pathways independent of G-protein activation, through the scaffolding of signaling complexes by β-arrestin, a component of the GPCR desensitization and internalization machinery (3). These two signaling modes harbor distinct functional properties, and in instances the same ligand can act as an agonist for one pathway but antagonist at the other. The selective or biased activation of a given pathway is commonly referred to as "functional selectivity" and can be easily demonstrated in heterologous systems especially when biased small molecule ligands are available (4) . Biased GPCR ligands may have high therapeutic potential as these receptors represent the largest targets of drugs on the market. However, determining the functional contributions of G-protein and β-arrestin signaling pathways to the biological actions of an endogenous ligand acting upon its receptor still remains a challenging undertaking. Dopamine (DA) is a neuromodulator that is known to regulate movement, reward, cognition, emotion, and affect. The dopamine D2 receptor (D 2 R) is a prominent GPCR that mediates the actions of DA. All typical antipsychotics, such as haloperidol, are potent D 2 R blockers (5), whereas atypical antipsychotics, such as aripiprazole and clozapine, have unique pharmacology, exhibiting weak partial agonist activity at D 2 R or reduced antagonist efficacy, respectively (6) . Previous studies have demonstrated the ability of D 2 Rs to engage different signal transduction pathways depending on the cellular complement of G proteins as well as their ability to regulate different physiological processes (7) (8) (9) . β-arrestin 2 knockout mice provided robust behavioral and biochemical evidence for a critical D 2 R/β-arrestin signaling pathway in the striatum (10) . Furthermore, neuronal selective deletion of GSK3β, a putative D 2 R/β-arrestin 2 effector, could reproduce the pharmacological blockade of D 2 Rs with antipsychotics (11) . Although these studies suggest that D 2 Rs, like many other GPCRs, use pleiotropic signaling pathways to mediate their effects, the brain DA system is uniquely complex, as diverse responses may also rely upon many other determinants. One well-documented variable is the mode of stimulation of DA receptors, which is a function of the tonic or phasic release of DA (12) . The expression profile of D 2 R is also complex, being expressed not only in DA synthesizing
Significance
The dopamine D2 receptor (D 2 R), a G protein-coupled receptor, can initiate signaling events through both activation of G proteins and interactions with β-arrestins. To begin to understand the contribution of these events in the physiology of the dopamine system, D 2 R was mutated to be functionally selective for each signaling pathway. The engineered receptors are functional in vitro and in vivo. Furthermore, both functions are essentially dissociable and mediate different physiological and pharmacological responses. These tools provide an additional but previously unavailable approach to elucidate the role of biased signaling in the multiple physiological actions of the dopamine system. neurons of the substantia nigra and ventral tegmental area where they function as presynaptic autoreceptors but also in GABAergic medium spiny neurons (MSNs), cholinergic interneurons of the striatum, and cortical neurons (13) , where they function as postsynaptic receptors. Thus, understanding the contributions of functional selectivity at D 2 R in intact biological systems is a challenge that cannot be elucidated in heterologous systems alone. To develop tools where this challenge can begin to be addressed, the Evolutionary Trace (ET) (14) approach was used to engineer D 2 R mutants that selectively interact with either G proteins or β-arrestins, designated [Gprot] D 2 R and [βarr] D 2 R, respectively. These mutants show separation of G-protein and β-arrestin interactions, and expression of these mutants in vivo in the mouse striatum provides proof-of-concept for their biological activity and discrete functions.
Results
Evolutionary Trace-Guided Mutagenesis of D 2 R. The ET method identifies amino acids that determine the function of a protein and map its functional sites when a structure is available (15, 16) . ET algorithms exploit protein orthologs and paralogs to correlate sequence variations with phylogenetic divergences and determine whether substitutions at a particular residue are likely to produce a functional change in the protein (17) . The predictive power of ET is further enhanced when specific crystal structures (18) and more sophisticated models of the evolution of structure and function can be applied (16, 19) . Here a combination of these approaches (cocrystals of receptors and signaling molecules as well as more sophisticated algorithms; Fig. S1 ) was used to identify residues in D 2 R that could be mutated to achieve functional selectivity. The residues that were identified as being potentially critical for functional selectivity are mapped onto a snake-like plot of D 2 R ( To achieve specific and robust separation of G protein-and β-arrestin-dependent interactions, Evolutionary Action (EA) (21) was used to predict residue changes. EA models the evolutionary relationship between genotype and phenotype as a smooth process upon which a mutation causes a small perturbation. Explicitly, if γ is the genotype sequence and φ is the fitness phenotype, EA postulates an evolutionary function f between them exists, such that
and f is differentiable so that the Evolutionary Action point mutation Δγ on fitness is f ′ðγÞ · Δγ = Δφ.
[2]
In practice, f remains unknown, but its derivative (or gradient) f′ is given by ET, and Δγ is given by substitution odds. The Evolutionary Action Eq. 2 is thus generally solvable for coding mutation of proteins and quantifies the effect of mutations over multiple scales, spanning molecular, clinical, and population genetics effects (21) (22) (23) (24) . Here, for each residue identified in Fig. 1 A and B, mutations were predicted and scored by EA according to how likely they would produce a phenotype (Table S1) . Each point mutation was tested for G-protein activity by cAMP inhibition and β-arrestin 2 recruitment by bioluminescent resonance energy transfer (BRET) (25) and fidelity of plasma membrane trafficking as well as lack of constitutive activity. These mutants were binned into four categories: (i) β-arrestinbiased, (ii) G protein-biased, (iii) deficient at both pathways, or (iv) unaffected at either pathway ( D 2 R (A135R M140D). Each of these mutations occurs within 20 amino acids of the DRY motif of TM3 (Fig. 1C) .
[Gprot] D 2 R mutations are more distal from the interacting regions of the Table S1 and Fig. S1 . Red residues, derived from TYY; green spheres, predicted from piET algorithm; yellow spheres, predicted from proximity to rhodopsin/transducin Gα subunit C-terminal fragment cocrystal; gray spheres, identified residues from β2AR/Gαβγ cocrystal in intracellular loop two. Ballesteros-Weinstein numbering identified for each transmembrane domain. The long N terminus (N-term) and intracellular loop three (IC3) were abridged. The same color scheme was used to highlight the residues on the structure of D 3 R (20) because D 3 R is the most closely related GPCR to D 2 R with an available crystal structure (81% sequence identity for transmembrane domains). (B) D 3 R structure is represented as a blue ribbon, and ET-identified residues are spheres. recently resolved cocrystals of receptors and G proteins or arrestin fragments, whereas [βarr] D 2 R mutations are more proximal (Fig. 1D) . The [Gprot] D 2 R mutant is derived from the more sophisticated ET algorithms (TYY and piET; Fig. S1 ), whereas [βarr] D 2 R arose from residues identified in the more specific crystal structures of receptors and G proteins (26, 27) . [Gprot] D 2 R and [βarr] D 2 R Display Distinct but Expected Properties. Each receptor was profiled for G-protein and β-arrestin activity. In addition, a negative control point mutation,
[D80A] D 2 R (28), was included in all experiments because this mutant has been shown to bind ligands and traffic to the plasma membrane but is deficient in signaling. As shown in Fig. 2A , [Gprot] D 2 R retained full efficacy and potency at cAMP inhibition compared with [WT] D 2 R, whereas [βarr] D 2 R and
[D80A] D 2 R are severely deficient. In contrast, β-arrestin 2 recruitment is retained and even enhanced in [βarr] D 2 R whereas both efficacy and potency are either lost or markedly reduced in [D80A] D 2 R and [Gprot] D 2 R as determined by BRET (Fig. 2B) .
Point mutations in GPCRs, especially ones that affect signaling, are notorious for inducing unstable proteins (29) . To address this concern, the membrane localization of [ (Fig. 2G) . However, the K D for the antagonist raclopride was virtually identical (Fig. 2H) , and the K I for DA was also unchanged (Fig. 2I) . Receptor internalization, as assessed by cell surface ELISA on live cells (30) , demonstrates predictable internalization patterns: [βarr] D 2 R and [WT] D 2 R internalize to the same degree (30%) as previously reported (31), whereas [Gprot] D 2 R and [D80A] D 2 R are severely deficient (Fig. 2J) .
The separation in apparent affinity for the endogenous ligand dopamine for cAMP inhibition, β-arrestin 2 recruitment, and internalization is 100-to 1,000-fold between the two engineered receptors, whereas the K D of raclopride remains unchanged. Similarly, the response of each receptor mutant would be greater than 90% distinct even at the highest physiological levels of dopamine (100 μM in Fig. 2 A, B , and J and Table S2 ). Additionally, the slight differences in expression levels of the various D 2 R mutants does not seem to affect their coupling potencies as increasing the amounts of transfected D 2 Rs has the same effects for [ The relationship between GPCR G protein-and β-arrestindependent signaling is complex. G protein-mediated signaling is rapid and transient, and engagement of β-arrestin inhibits the G-protein pathways. In addition, formation of the GPCR/β-arrestin complex normally depends upon phosphorylation of the receptor (32) . Moreover, G proteins and β-arrestins can engage the same pathway but with distinct cellular consequences. One welldocumented example of this is the MAP kinase cascade (33) . To address this relationship, two related transcriptional reporters for MAP kinase signaling were transfected along with the mutated D 2 Rs in HEK 293T cells. As shown in Fig. 3 A and B (Fig. S3B) . Probing ERK phosphorylation through Western blot analysis revealed activation by [βarr] D 2 R compared with [D80A] D 2 R or untransfected cells only when β-arrestin 2 is overexpressed ( Fig. 3 C and D) . In contrast, [Gprot] D 2 R activated ERK phosphorylation regardless of β-arrestin expression, compared with
[D80A] D 2 R. This indicates that D 2 R activates canonical MAP kinase activity through G proteins, whereas β-arrestin may produce noncanonical ERK activity under conditions of enhanced β-arrestin or kinase expression, as observed in other GPCR systems (34) . (Fig. 4A) . Each D 2 R construct was injected bilaterally into the dorsal striatum (caudate putamen) and the ventral striatum (nucleus accumbens) (Fig. 4B) . Extent of viral transduction was assessed by staining for the HA epitope tag on the N terminus of D 2 Rs (Fig. 4C) . Neuronal specificity of expression was achieved using the Adora2A-Cre mouse line, which selectively expresses Cre in D 2 R-expressing medium spiny neurons (MSNs) but not presynaptic DA projection cells (36) , and these Adora2A-Cre mice were also crossed to a mouse strain with β-arrestin 2 floxed to allow for specific deletion of β-arrestin 2 in indirect pathway MSNs.
[ D 2 R yielded a twofold to fourfold increase in striatal D 2 R expression as measured by ligand binding (Fig. 4D , expression in Adora2A-Cre, and Fig. 4E , expression when β-arrestin 2 is genetically deleted). Overexpression of the [WT] D 2 R led to a ∼1.5-fold potentiation in the amphetamine induced locomotor response (Fig. 4F) .
[βarr] D 2 R overexpression led to a similar potentiation, whereas the [Gprot] D 2 R overexpression was much less effective. However, to demonstrate construct validity, the same 
Discussion
DA is an important regulator of both CNS and peripheral physiological homeostasis. Disruptions in the function of DA have been associated with schizophrenia, depression, mania, attention deficit disorders, drug abuse, and Parkinson's disease in the CNS and hypertension and prolactinemia in the periphery (37) . DA exerts its function through two major GPCRs: D 2 R and D 1 R (as well as the D 1 R-like D 5 R and D 2 R-like D 3 R and D 4 R receptors). The results described here provide a functional template to begin to investigate the in vivo pharmacological, biochemical, and neuronally selective actions of D 2 R. Precise molecular control was achieved by engineering D 2 Rs specifically designed to interact with either G proteins or β-arrestins, and these receptors can be reconstituted in cell culture or in specific neuronal populations in vivo.
Over the last several years, state-of-the-art optogenetic (38) and pharmacogenetic (39) approaches have been developed to map brain pathways and cellular functions of neuronal populations. However, these approaches are not amenable to the elucidation of molecular mechanisms because they are not designed to manipulate the specific biochemical mechanisms of an endogenous ligand through its cognate receptor. Additionally, optogenetic or pharmacogenetic control of intracellular signaling cascades, such as G proteins (40) or ERK (41), do not allow for the interrogation of endogenous ligand dynamic changes or the effect of therapeutics to the system. Understanding the biology of D 2 R will require determinants such as the contextual influence of phasic and tonic DA release (12) and the monitoring of therapeutics, such as antipsychotics. Although less widely applicable, functionally selective GPCRs are a desirable alternative because they resolve many of the limitations of the more general approaches.
Previously, biochemical studies in mice carrying complete deletion of β-arrestin 2 (10) or cell type-specific genetic deletion of GSK3β (11) have provided evidence for the importance of the β-arrestin 2-mediated D 2 R signaling pathway in the actions of DA. However, evidence from such studies is limited by the fact that β-arrestin 2 interacts with multiple GPCRs and GSK3β is a signaling hub downstream of many signaling networks, including both G proteins (42) and β-arrestin 2 (10). The current approach injected bilaterally into the dorsal and ventral striatum with each injection site indicated by the red dots, and a total of 3 μL was injected into the striatum of each mouse. CPu, caudate putamen; AcbC, nucleus accumbens, core; AcbSh, nucleus accumbens, shell. (C) Representative staining pattern of the N-terminal HA tagged D 2 R shows transduction of a majority of the dorsal striatum and at least 50% of the ventral striatum with variable transduction in the olfactory tubercle. Radioligand binding revealed a twofold to fourfold overexpression of each receptor as determined from membranes prepared from striatal dissections from Adora2A-Cre (D) and Adora2A-Cre::β-arrestin 2 flox (E) mice (*P < 0.05 Newman-Keuls post hoc compared with Cre (−) controls after one-way ANOVA P < 0.05, SEM, n = 4-6). (F) Potentiation of amphetamine-induced locomotion in mice when D 2 R is overexpressed (*P < 0.05 bonferroni post hoc compared with [D80A] D 2 R after repeated measures two-way ANOVA P < 0.05 for receptor expression type SEM, n = 11-12, color coded for receptor type). (G) The amphetamine response potentiation of [WT] D 2 R and [βarr] D 2 R is abolished when β-arrestin 2 is genetically deleted from D 2 R-expressing medium spiny neurons (*P < 0.05 bonferroni post hoc compared with [D80A] D 2 R after repeated measures two-way ANOVA P < 0.05 for receptor expression type SEM, n = 8-13). more specifically targets D 2 R, and these pathway-specific mutant D 2 Rs were developed to begin to elucidate the contribution of individual pathways to physiological and pharmacological DA responses. Biased mutants similar to those in other GPCRs like the β2-adrenergic (TYY) and angiotensin 1A (DRY) receptors (43, 44 ) generated unstable proteins when engineered into D 2 R. Additionally, several D 2 R mutants have also been generated and shown to affect β-arrestin and GPCR kinase interactions (45, 46) , postendocytic trafficking (31), desensitization (47) , and resensitization (48) . Although these D 2 R mutants have informed various aspects of function and regulation of D 2 Rs, consideration of some of these mutants for the work described here did not fulfill all necessary inclusion criteria.
The pharmacological fidelity (trafficking, ligand binding and signal transduction) of [Gprot] D 2 R and [βarr] D 2 R revealed robust and specific engagement of each pathway. Through sequential iterations (Fig. S2) , each mutation converged on transmembrane domain three (TM3), an alpha helix critical for the transmission of conformational changes from ligand binding to signaling molecules (49) . These changes in signal transduction allowed for the elucidation of complex signaling paradigms. MAP kinase cascades have previously been shown to be activated downstream of G proteins and β-arrestins (25, 26) , but as shown here, [Gprot] D 2 R is responsible for a major component of the ERK signaling cascade with the normal complement of kinases and β-arrestins present in HEK 293T cells. However, overexpression of β-arrestin 2 revealed the ability of [βarr] D 2 R to couple to ERK. It is interesting to note that although [Gprot] D 2 R did not significantly enhance the transcriptional activity, there was a small potentiation in pERK observed compared with [WT] D 2 R. Taken together, these data indicate that receptor transducer elements, such as MAP kinases, may also exhibit functional selectivity. Finally, to assess the in vivo function of the engineered receptors we used a neuronally selective overexpression approach, which carries the caveat of assessing function in the presence of the normal signaling of endogenous receptors. Despite this limitation, expression of mutant D 2 Rs in D 2 R+MSNs revealed marked differences in their ability to affect responses to the psychotropic drug amphetamine. The [βarr] D 2 R was more effective at enhancing the amphetamine response than the [Gprot] D 2 R. Although the extent of the separation was surprising, it is consistent with previous genetic manipulation studies, which have predicted an important role for the D 2 R/β-arrestin 2 pathway in vivo as genetic deletion of β-arrestin 2 has been shown to decrease the locomotor response to amphetamine (8, 10) . [Gprot] D 2 R only slightly potentiated the amphetamine response, and this trend was enhanced by genetic deletion of β-arrestin 2 in D 2 R expressing MSNs. In contrast, [WT] D 2 R and [βarr] D 2 R lost their potentiation of the amphetamine response when β-arrestin 2 was deleted. These data demonstrate the complexity of even basic GPCR signaling events and should allow for insights into the biased actions of the endogenous neurotransmitter.
In summary, functionally selective or biased signaling engineered GPCRs can display in vivo biological activity and mediate distinct pharmacological responses. The robust separation of signal achieved with [Gprot] D 2 R and [βarr] D 2 R will allow for direct elucidation of more complex functional selectivity principles when applied to diverse D 2 R systems. These mutants differ from [WT] D 2 R by only two amino acids and yet have specific D 2 R functions disrupted. Functional selectivity has considerable therapeutic potential, but the molecular details have been obscured by the complexity of receptor activation. Furthermore, some signaling events can only be understood in the context of the in vivo architecture (50) . [Gprot] D 2 R and [βarr] D 2 R are unique tools that should allow for a better understanding of the molecular, cellular, and physiological actions of dopamine as well as provide a template for the development of small molecules with therapeutic predictive value.
Materials and Methods
Evolutionary Trace. Multiple rounds of ET-guided mutagenesis were conducted on D 2 R. Each round took advantage of enhancements to the Evolutionary Trace method and GPCR crystallography. The previously reported (43) β-adrenergic 2A receptor TYY served as a starting point for D 2 R mutagenesis. β2AR-TYY was previously shown to signal through β-arrestins but not G proteins. The first round targeted these homologous positions in D 2 R (T69, Y133, and Y209). Based on the initial results of TYY mutations, new targets were added based on ET importance and structural location. Substitutions for targeted positions were based on homology in the multiple sequence alignment. In order for D 2 R to be functional, mutations to cognate amino acids found in other GPCRs at the equivalent sequence position were selected.
Due to the variation in the GPCR loop regions, the transmembrane domains and loops were analyzed separately. The multiple sequence alignment of the transmembrane region was made up of 2512 Class A GPCRs. These sequences were gathered from GPCRDB, aligned, and filtered for the 195 gapless seven transmembrane helix residues. We used the updated pair interaction ET algorithm (piET) (16) , which achieves greater accuracy by taking into account the residue contacts seen in a structure, here the crystal structure of rhodopsin in complex with the C terminus peptide of the endogenous G protein (27) . The residues targeted for mutation were selected based on their evolutionarily importance (top 5%) and proximity to the C terminus peptide (within 12 Angstroms, the residues in DRY and NPXXY motifs being ignored). The Evolutionary Action algorithm (21) was used to identify substitutions with varying harshness.
An analysis specific to D 2 R was used to identify the key ET residues in the second intracellular loop region. The crystal structure of β2AR in complex with Gαs (26) was also used to narrow down to the crucial residues for G-protein activation. The multiple sequence alignment for D 2 R entire sequence (including loops) was made of 66 homologs extracted from a BLAST analysis of the National Center for Biotechnology Information (NCBI) Reference Sequence database where we filtered based on protein length (90% of the query protein) and sequence identity (>60%). This was to ensure we use the most relevant information for ET analysis. Substitutions for targeted positions were also identified with the Evolutionary Action algorithm.
Mutagenesis PCR. The Agilent Technologies QuikChange mutagenesis kit was used to carry out all mutagenesis according to manufacturer's instructions. Primers were designed as instructed, with the minimum amount of nucleotide changes required to achieve a mutation. Multiple point mutations were created by using the same primers for single point mutations on already mutated constructs. All constructs were confirmed to have no coding errors by sequencing.
Cell Culture and Transfections. HEK 293T American Type Culture Collection (ATCC) cells were cultured and transfected as previously reported (25) . Please see SI Materials and Methods for a description of the receptor activity assays presented in Figs. 2 and 3.
Mouse Lines. All mouse studies were conducted in accordance with the National Institutes of Health Guidelines for Animal Care and Use and with an approved animal protocol from the Duke University Animal Care and Use Committee. Please see SI Materials and Methods for more detailed description of the mouse work presented in Fig. 4 .
Data Handling. All dose-response curves were analyzed using the nonlinear regression function Y = Bottom + (Top − Bottom)/(1 + 10^((LogEC50 − X))) of GraphPad Prism 5. All binding curves were fit to Y = Bmax*X/(K d + X). Statistical analyses were performed as reported in figure legends using GraphPad Prism 5.
